Drug change | Mean duration of RA at baseline (years) | ACR20 (%) | ACR50 (%) | ACR70 (%) | DAS28 (mean change from baseline) | DAS28 <2.6 (%) | HAQ (mean change from baseline) |
---|---|---|---|---|---|---|---|
*Patients were eligible for corticosteroid and/or MTX dosage reductions after receiving adalimumab treatment for at least 6 months. Last visits were at 8–59 months from the start of adalimumab treatment. | |||||||
Steroid decrease (n = 51) | 10.8 | 78 | 55 | 28 | –2.9 | 22 | –0.67 |
Steroid no change (n = 29) | 11.6 | 76 | 52 | 24 | –2.5 | 18 | –0.58 |
MTX decrease (n = 92) | 11.1 | 75 | 55 | 34 | –2.7 | 27 | –0.73 |
MTX no change (n = 110) | 12.3 | 67 | 44 | 24 | –2.5 | 16 | –0.65 |
MTX increase (n = 15) | 14.5 | 53 | 33 | 20 | –1.7 | 7 | –0.55 |
MTX and steroid decrease (n = 25) | 10.1 | 76 | 48 | 20 | –3.0 | 24 | –0.65 |